Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
T. Akamatsu (Shizuoka, Japan), H. Nakayasu (Shizuoka, Japan), K. Tamura (Shizuoka, Japan), T. Masuda (Shizuoka, Japan), S. Takahashi (Shizuoka, Japan), Y. Tanaka (Shizuoka, Japan), H. Watanabe (Shizuoka, Japan), Y. Kishimoto (Shizuoka, Japan), K. Oishi (Shizuoka, Japan), M. Saigusa (Shizuoka, Japan), A. Yamamoto (Shizuoka, Japan), S. Morita (Shizuoka, Japan), K. Asada (Shizuoka, Japan), T. Shirai (Shizuoka, Japan). Association between antifibrotic medications and pneumothorax or pneumomediastinum in patients with idiopathic pulmonary fibrosis. 1854

Member's Comments

No comment yet.

Related content which might interest you: Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis Source: Eur Respir J, 50 (4) 1701157; 10.1183/13993003.01157-2017 Year: 2017 Clinical features of patients with idiopathic pulmonary upper lobe-dominant fibrosis Source: International Congress 2016 – Orphan diseases I Year: 2016 Outcomes of cystic fibrosis patients after spontaneous pneumothorax Source: Eur Respir J 2007; 30: Suppl. 51, 387s Year: 2007 Pulmonary hypertension in patients with idiopathic pulmonary fibrosis and combined pulmonary fibrosis and emphysema: hemodynamic severity Source: International Congress 2018 – Pulmonary hypertension in lung diseases and the role of the right ventricle Year: 2018 Initial clinical experience with nintedanib for treatment of idiopathic pulmonary fibrosis (IPF): About 20 cases Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Treatment with antifibrotic agents in idiopathic pleuroparenchymal fibroelastosis with usual interstitial pneumonia Source: ERJ Open Res, 7 (1) 00196-2020; 10.1183/23120541.00196-2020 Year: 2021 Relationship between nintedanib exposure and adverse events in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF treatment II Year: 2016 Concomitant medications and clinical outcomes in idiopathic pulmonary fibrosis Source: Eur Respir J, 54 (6) 1901188; 10.1183/13993003.01188-2019 Year: 2019 RISE-IIP: Riociguat for the treatment of pulmonary hypertension associated with idiopathic interstitial pneumonia Source: International Congress 2017 – New insights into pulmonary hypertension from recent trials Year: 2017 Acute exacerbations of idiopathic pulmonary fibrosis and the role of corticosteroids Source: Breathe, 16 (3) 200086; 10.1183/20734735.0086-2020 Year: 2020 Registry of idiopathic pulmonary fibrosis patients Source: International Congress 2016 – Russia Session Year: 2016 Clinical characteristics and survival in patients with idiopathic pulmonary fibrosis with and without associated emphysema Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Exacerbation of idiopathic pulmonary fibrosis Source: International Congress 2016 – Russia Session Year: 2016 Non-pulmonary comorbidities in idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: clinical aspects Year: 2015 Cough in idiopathic pulmonary fibrosis Source: Eur Respir Rev 2016; 25: 278-286 Year: 2016 The causes of hemoptysis and lung hemorrhage in patients with pulmonary sarcoidosis Source: Annual Congress 2011 - Acute respiratory failure Year: 2011 Anti-fibrotic effects of pirfenidone in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Antifibrotic choice in idiopathic pulmonary fibrosis Source: International Congress 2018 – Idiopathic interstital pneumonias other than idiopathic pulmonary fibrosis (IPF) Year: 2018 Effects of short-term pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis Source: Eur Respir J 2006; 28: Suppl. 50, 628s Year: 2006